Trial
NCT07057479
Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin
Phase IIIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Eurofarma Laboratorios S.A.
Collaborators
—
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention
Fixed-dose combination of SGLT2 inhibitor and thiazolidinedione
Why stopped
Strategic change in development priorities
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-18